<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02747485</url>
  </required_header>
  <id_info>
    <org_study_id>2016-11</org_study_id>
    <secondary_id>2015-A00587-42</secondary_id>
    <nct_id>NCT02747485</nct_id>
  </id_info>
  <brief_title>Impact of Diffuse Myocardial Fibrosis on the Ventricular Function in Regurgitant Left-Sided Valve Heart Diseases ( The DIFFUsE Study)</brief_title>
  <acronym>DIFFUsE</acronym>
  <official_title>Impact of Diffuse Myocardial Fibrosis on the Ventricular Function in Regurgitant Left-Sided Valve Heart Diseases &quot; The DIFFUsE Study &quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      New strategies are needed to early detect myocardial involvement in these diseases.&#xD;
      Histological studies showed that diffuse fibrosis and cardiomyocyte hypertrophy precede the&#xD;
      LV remodelling (dilatation) observed by cardiac imaging. Quantification of LV diffuse&#xD;
      myocardial fibrosis using magnetic resonance imaging (MRI) could reach this goal. Recently,&#xD;
      contrast enhanced cardiac MRI has been used to measure the extracellular volume fraction&#xD;
      (ECV) of the myocardium, and it has been able to detect diffuse myocardial fibrosis. In&#xD;
      diseases in which increased collagen deposition enlarges the extra-cellular space, the ECV&#xD;
      can act as a fibrosis index. ECV is correlated with the amount of fibrosis measured by&#xD;
      histology. Left ventricular overloads induced by regurgitant VHD result in cardiomyocyte&#xD;
      hypertrophy and diffuse fibrosis. Other methods can be used to estimate the degree of&#xD;
      myocardial fibrosis such as the serum level of galectine-3 or ST2. Moreover, although the&#xD;
      pathophysiological mechanisms leading to the occurrence of myocardial fibrosis differ in&#xD;
      patients with various cardiac diseases, the cellular effectors of fibrotic remodelling are&#xD;
      common and involve similar signalling pathways. At the cellular level, key progression of&#xD;
      ventricular hypertrophy is associated with increased cardiomyocytes apoptosis and fibrosis,&#xD;
      suggesting that these two processes are responsible for the transition.&#xD;
&#xD;
      To our knowledge, no study has analysed the impact of the rate of myocardial diffuse&#xD;
      fibrosis, non-invasively estimated by ECV, in the risk of LV dysfunction during MR and AR,&#xD;
      especially after surgery. The measurement of ECV could become an important tool for risk&#xD;
      stratification in left-sided regurgitant VHD. Thus, it would provide an early marker of LV&#xD;
      myocardial involvement before the occurrence of global remodeling, might help physicians in&#xD;
      surgical decision, and would improve prognosis. This is an innovative original project&#xD;
      because it uses modern imaging modalities to answer to a crucial question. The clinical&#xD;
      implications would be important because this work would modify the international surgical&#xD;
      indications of MR and AR in order to finally improve the prognosis of patients with this&#xD;
      frequent heart disease. Moreover, investigators will analyze the genetic factors that can&#xD;
      influence the myocardial reaction resulting from these regurgitations, which will improve the&#xD;
      quality of this work and offer new future perspectives.&#xD;
&#xD;
      Investigators hypothesize that the ECV measurement could be used as an early predictor of LV&#xD;
      dysfunction in the left-sided valve regurgitations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the rate of diffuse myocardial fibrosis</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlations between ECV and the global longitudinal strain and the serum level of Galectin-3 and ST2</measure>
    <time_frame>42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlations between ECV changes and genetic factors</measure>
    <time_frame>42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlations between ECV and the severity of the regurgitation</measure>
    <time_frame>42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlation between ECV and the myocardial deformation quantified by speckle tracking echocardiography (2D Strain)</measure>
    <time_frame>42 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">316</enrollment>
  <condition>Valve Heart Diseases</condition>
  <arm_group>
    <arm_group_label>organic left-sided regurgitant valve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac MRI</intervention_name>
    <arm_group_label>organic left-sided regurgitant valve</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood samples</intervention_name>
    <description>Serum levels of biomarkers of myocardial fibrosis (galectine-3 and ST2) will be measured</description>
    <arm_group_label>organic left-sided regurgitant valve</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>myocardial biopsy</intervention_name>
    <arm_group_label>organic left-sided regurgitant valve</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>blood samples</intervention_name>
    <description>extract DNA to look for genomic mutations associated with the disease.</description>
    <arm_group_label>organic left-sided regurgitant valve</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All consecutive patients referred for organic MR and/or AR at least moderate to severe&#xD;
             according to the ESC guidelines criteria‚Å¥ will be eligible. The moderate to severe&#xD;
             criteria will defined by echocardiography as followed:&#xD;
&#xD;
          -  MR: an effective regurgitant orifice area (EOA) &gt;30mm2 and/or a regurgitant volume&#xD;
             (RV) &gt;45mL&#xD;
&#xD;
          -  AR: an EOA &gt;20mm2 and/or a RV &gt;45mL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Impossibility to maintain a decubitus position&#xD;
&#xD;
          -  Arrhythmia that do not allow an ECG synchronization during MRI&#xD;
&#xD;
          -  Hemodynamic instability&#xD;
&#xD;
          -  Indication of urgent surgery&#xD;
&#xD;
          -  Known coronary artery disease&#xD;
&#xD;
          -  Severe arterial hypertension&#xD;
&#xD;
          -  Cardiomyopathy&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Gadolinium intolerance&#xD;
&#xD;
          -  Implantable medical devices that do allow to perform MRI&#xD;
&#xD;
          -  Severe renal insufficiency with clearance &lt;35 mL/min&#xD;
&#xD;
          -  Vulnerable patients&#xD;
&#xD;
          -  Acute infective endocarditis&#xD;
&#xD;
          -  Aortic dissection&#xD;
&#xD;
          -  Moderate or severe mitral stenosis (mitral area &lt;1.5cm2/m2)&#xD;
&#xD;
          -  Moderate or severe aortic stenosis (aortic area &lt;0.8cm2/m2, or Vmax&gt;3m/s, or mean&#xD;
             gradient&gt;30mmHg)&#xD;
&#xD;
          -  Previous cardiac surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine GEINDRE</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>THUNY franck, PU PH</last_name>
    <email>franck.thuny@ap-hm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>AVIERINOS Jean-Francois, PU PH</last_name>
    <email>jfavierinos@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <state>Bouche DU Rhone</state>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>THUNY FRANCK</last_name>
      <email>franck.thuny@ap-hm.fr</email>
    </contact>
    <contact_backup>
      <last_name>AVIERINOS JEAN-FRANCOIS</last_name>
      <email>jfavierinos@ap-hm.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>April 19, 2016</study_first_submitted>
  <study_first_submitted_qc>April 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2016</study_first_posted>
  <last_update_submitted>March 4, 2019</last_update_submitted>
  <last_update_submitted_qc>March 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

